View in EDS PDF Full Text

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.

Saved in:
Bibliographic Details
Title: Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
Authors: Nardo M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Reilley MJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Biter AB; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lim J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bean SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nguyen LM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bhosale PR; Abdominal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ager CR; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Couillault CA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Curran MA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2025 Feb 07; Vol. 8 (2), pp. 89-98. Date of Electronic Publication: 2025 Feb 07 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Innovative Healthcare Institute Country of Publication: United States NLM ID: 101768397 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-017X (Electronic) Linking ISSN: 2590017X NLM ISO Abbreviation: J Immunother Precis Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39959251
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Nardo+M%22">Nardo M</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gouda+MA%22">Gouda MA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Reilley+MJ%22">Reilley MJ</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Biter+AB%22">Biter AB</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Lim+J%22">Lim J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Bean+SA%22">Bean SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Nguyen+LM%22">Nguyen LM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Bhosale+PR%22">Bhosale PR</searchLink>; Abdominal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ager+CR%22">Ager CR</searchLink>; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Couillault+CA%22">Couillault CA</searchLink>; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+AM%22">Tsimberidou AM</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rodon+J%22">Rodon J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Subbiah+V%22">Subbiah V</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Karp+DD%22">Karp DD</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Curran+MA%22">Curran MA</searchLink>; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101768397%22">Journal of immunotherapy and precision oncology</searchLink> [J Immunother Precis Oncol] 2025 Feb 07; Vol. 8 (2), pp. 89-98. <i>Date of Electronic Publication: </i>2025 Feb 07 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Innovative+Healthcare+Institute%22">Innovative Healthcare Institute </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101768397 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>2590-017X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222590017X%22">2590017X </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Precis Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39959251
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.36401/JIPO-24-17
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 89
    Titles:
      – TitleFull: Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Nardo M
      – PersonEntity:
          Name:
            NameFull: Gouda MA
      – PersonEntity:
          Name:
            NameFull: Reilley MJ
      – PersonEntity:
          Name:
            NameFull: Biter AB
      – PersonEntity:
          Name:
            NameFull: Lim J
      – PersonEntity:
          Name:
            NameFull: Bean SA
      – PersonEntity:
          Name:
            NameFull: Nguyen LM
      – PersonEntity:
          Name:
            NameFull: Bhosale PR
      – PersonEntity:
          Name:
            NameFull: Ager CR
      – PersonEntity:
          Name:
            NameFull: Couillault CA
      – PersonEntity:
          Name:
            NameFull: Piha-Paul SA
      – PersonEntity:
          Name:
            NameFull: Fu S
      – PersonEntity:
          Name:
            NameFull: Tsimberidou AM
      – PersonEntity:
          Name:
            NameFull: Yap TA
      – PersonEntity:
          Name:
            NameFull: Naing A
      – PersonEntity:
          Name:
            NameFull: Rodon J
      – PersonEntity:
          Name:
            NameFull: Subbiah V
      – PersonEntity:
          Name:
            NameFull: Karp DD
      – PersonEntity:
          Name:
            NameFull: Curran MA
      – PersonEntity:
          Name:
            NameFull: Hong DS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 02
              Text: 2025 Feb 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2590-017X
          Numbering:
            – Type: volume
              Value: 8
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Journal of immunotherapy and precision oncology
              Type: main
ResultId 1